Focus Partners Wealth
SCTX

Focus Partners Wealth’s Scribe Therapeutics Inc SCTX Stock Holding History

Focus Partners Wealth’s Portfolio SCTX Stock Details SCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$369K Buy
+20,025
New +$528K ﹤0.01% 2182

Other funds holding SCTX

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Menlo Ventures Management
Menlo Ventures Management Menlo Park, California $241M AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Focus Partners Wealth's SCTX Position: Q3 2026 in Review

Focus Partners Wealth opened a new position in Scribe Therapeutics Inc (SCTX) in Q3 2026: 20,025 shares worth $369K. The stake represents ﹤0.01% of the portfolio and ranks #2182 among its holdings.

23 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.

  • Focus Partners Wealth held 20,025 shares of Scribe Therapeutics Inc worth $369K as of Q3 2026.
  • Scribe Therapeutics Inc was a new Focus Partners Wealth position in Q3 2026.
  • Scribe Therapeutics Inc made up ﹤0.01% of Focus Partners Wealth's portfolio in Q3 2026, its #2182 holding.
  • 23 funds tracked by Wall St. Rank held Scribe Therapeutics Inc as of Q3 2026.

Based on Focus Partners Wealth's 13F filing for Q3 2026, filed 12 Nov 2026.